The startup develops protein-RNA conjugates aimed at enhancing immune responses in oncology to target and eliminate cancer cells. Their approach addresses the need for more effective cancer treatments by leveraging the body's immune system to improve therapeutic outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Current cancer treatments often lack the precision needed to target cancer cells effectively, leading to significant side effects and limited efficacy. Enhancing the body's natural immune response to specifically target and eliminate cancer cells remains a challenge.
Solution
This startup is developing protein-RNA conjugates designed to stimulate and enhance the immune system's ability to recognize and destroy cancer cells. By combining the specificity of proteins with the immunostimulatory properties of RNA, the conjugates aim to deliver targeted therapeutic effects directly to the tumor microenvironment. This approach seeks to improve treatment outcomes while minimizing damage to healthy tissues, offering a more precise and effective cancer therapy. The technology leverages the body's own defenses to fight cancer, potentially leading to more durable responses and improved patient survival.
Target Audience
The primary target audience includes oncology researchers, pharmaceutical companies, and clinical oncologists seeking innovative and targeted cancer immunotherapies.
Features
- Protein-RNA conjugates engineered for targeted delivery to cancer cells.
- Enhanced immune stimulation through specific RNA sequences.
- Modulation of the tumor microenvironment to promote immune cell infiltration.
- Increased specificity to minimize off-target effects and toxicity.